A research team at the Medical University of South Carolina reports in Cells that the complement system, part of the body's natural immune defenses, is a key driver of inflammatory responses that ...

Six-step framework: New guidance combines supportive care, steroids, immunosuppressants, plasma therapy, complement inhibitors, and transplants for C3G. Targeting root cause: FDA-approved and ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The complement inhibitors are the latest ...

Two complement inhibitors tied to increased risk of wet AMD, but data called suspect ...

Expert panelists evaluate results regarding complement inhibitor trials for utilization in PNH management. Several complement inhibitors have been approved since eculizumab, including ravulizumab, a ...

The complement inhibitors market is projected to grow, driven by the rising prevalence of complement-mediated diseases, intensified R&D efforts, and biotechnological advancements enabling novel ...

The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...

A single-center study suggests complement inhibitors do not reduce the severity of a COVID-19 Omicron infection in patients with paroxysmal nocturnal hemoglobinuria (PNH). A COVID-19 infection can ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video from the American Academy of Ophthalmology meeting, Michael W. Stewart, MD, highlights a ...

(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...